Aegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as Key
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Adamas Pharma (ADMS) Sees Red-to-Green Move
December 24, 2015 11:28 AM ESTAfter trading down as much as 8% earlier, yesterday's big mover Adamas Pharma (NASDAQ: ADMS) is back in positive territory.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit Suisse
December 24, 2015 7:37 AM ESTCredit Suisse analyst V. Divan reiterated an Outperform rating and raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $37.00 (from $35.00) after raising the probability of success for ADS-5102 to 90% (from 80%) on the back of encouraging topline phase 3 data for their lead internal asset... More
Adamas Pharma (ADMS) Ramps Into the Close
December 23, 2015 3:38 PM ESTAdamas Pharma (NASDAQ: ADMS) ramps into the close. Shares are up 73.6% and near the highs after earlier announcing statistically significant ADS-5102 Phase 3 EASE LID data.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & Company
December 23, 2015 2:18 PM ESTNeedham & Company analyst Serge Belanger reiterated a Buy rating and raised his price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $38.00 (from $33.00) after the company reported positive top-line results from its first ph 3 study evaluating ADS-5102 in the treatment of levodopa-induced dyskinesia (LID) in Parkinson's... More
